Skip to main content

Table 3 Frequency of hospitalizations due to bone complications

From: Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review

Outcome

At-risk perioda

EU5b

N = 813

France

N = 146

Germany

N = 175

Italy

N = 173

Spain

N = 141

UK

N = 173

Hospitalizations due to bone complications by at-risk period, n (%)c

 Any bone complication

Overall

119 (15)

20 (14)

33 (19)

22 (13)

20 (14)

24 (14)

Period 1

73 (9)

11 (8)

21 (12)

14 (8)

14 (10)

14 (8)

Period 2

29 (4)

4 (3)

10 (6)

4 (2)

3 (2)

7 (4)

Period 3

41 (5)

9 (6)

11 (6)

6 (4)

7 (5)

7 (4)

Hospitalizations due to bone complications by type of bone complication and at-risk period, n (%)d

 PF

Overall

79 (66)

11 (55)

26 (79)

13 (59)

16 (80)

15 (63)

Period 1

54 (74)

6 (55)

19 (91)

8 (57)

13 (93)

11 (79)

Period 2

11 (37)

1 (25)

3 (30)

2 (50)

0

4 (57)

Period 3

24 (58)

5 (56)

8 (72)

3 (50)

5 (71)

3 (43)

 SCC

Overall

20 (17)

4 (20)

4 (12)

4 (18)

2 (10)

5 (21)

Period 1

15 (21)

4 (36)

2 (10)

2 (14)

2 (14)

4 (29)

Period 2

2 (8)

0

0

0

0

2 (29)

Period 3

7 (18)

1 (11)

2 (18)

2 (33)

0

2 (29)

 RB

Overall

46 (39)

8 (40)

14 (42)

4 (18)

5 (25)

13 (54)

Period 1

21 (28)

5 (46)

4 (19)

3 (21)

0

6 (43)

Period 2

16 (55)

2 (50)

5 (50)

1 (25)

3 (100)

5 (71)

Period 3

17 (41)

4 (44)

5 (46)

0

3 (43)

4 (57)

 SB

Overall

36 (30)

5 (25)

12 (36)

11 (50)

2 (10)

5 (21)

Period 1

20 (28)

1 (9)

8 (38)

7 (50)

1 (7)

4 (29)

Period 2

10 (35)

1 (25)

4 (40)

2 (50)

1 (33)

2 (29)

Period 3

9 (21)

3 (33)

1 (9)

3 (50)

1 (14)

0

  1. EU5 five European countries (France, Germany, Italy, Spain and the UK), PF pathologic fracture, RB radiation to bone, SB surgery to bone, SCC spinal cord compression, UK United Kingdom
  2. aOverall: from multiple myeloma diagnosis to disease progression following first-line treatment; period 1: before initiation of induction therapy; period 2: during active first-line therapy; period 3: after treatment discontinuation
  3. bAggregated EU5 data have been weighted based on the multiple myeloma incidence in each country so base sizes for individual countries may not equal the EU5 total
  4. cExpressed as a percentage of the total number of patients
  5. dExpressed as a percentage of the number of patients who were hospitalized owing to a bone complication